Jazz Licenses Sumitomo’s Narcolepsy Drug for US$50 M Upfront
By Lucy Haggerty
Pharma Deals Review: Vol 2022 Issue 5 (Table of Contents)
Published: 7 May-2022
DOI: 10.3833/pdr.v2022.i5.2689 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In an attempt to expand its sleep disorder franchise, Jazz Pharmaceuticals has agreed to in-license Sumitomo Pharma’s Phase I orexin-2 receptor agonist, DSP-0187, for the potential treatment of narcolepsy, idiopathic hypersomnia and other sleep disorders...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS